SYNDROMIC MULTIPLEX PANELS MARKET: Strategies and Trends, Forecasts by Syndrome, Place, Product and Country with Market Analysis and Executive Guides 2024 to 2028
“The Syndromic Multiplex Diagnostics market enters a new post-pandemic growth phase as new entrants jockey for position in a new diagnostic world…..”
Publication date: November 2023
Page count: 455
Access: Licensed access; including next edition(s) when published during the subscription purchase period
Your report purchase is provided on a 12-month subscription basis from the date you receive your report. You will receive at least one additional edition of the complete report during this 12 month period for ongoing access to real-world, actionable insights.
The COVID pandemic has ushered in a new world of infectious disease diagnostics. Can an already rapidly growing market expand even faster? Find out all about it in this latest report on Syndromic Multiplex Diagnostics.
Syndromic testing is proving itself in the market. players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against antimicrobial resistance (AMR). The two key trends of point of care (POC) testing and molecular diagnostics (MDx) are meeting with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. Learn about this market including the issues and outlooks.
In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.
The report forecasts the market size out to 2027 and includes detailed breakouts for 14 countries and 5 regions.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options however your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
All report data is available in Excel format on request with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School